Aldeyra Therapeutics Inc Share Price Today: Live Updates & Key Insights

Aldeyra Therapeutics Inc share price today is $1.85, up -1.09%. The stock opened at $1.93 against the previous close of $1.83, with an intraday high of $2.03 and low of $1.795.

Aldeyra Therapeutics Inc Share Price Chart

Aldeyra Therapeutics Inc

us-stock
To Invest in {{usstockname}}
us-stock

Aldeyra Therapeutics Inc Share Price Performance

$1.85 -0.0109(-1.09%) ALDX at 23 Mar 2026 11:57 AM Biotechnology
Lowest Today 1.795
Highest Today 2.03
Today’s Open 1.93
Prev. Close 1.83
52 Week High 6.81
52 Week Low 1.07
Day’s Range: Low 1.795 High 2.03
52-Week Range: Low 1.07 High 6.81
1 day return -
1 Week return -57.15
1 month return -63.65
3 month return -67.38
6 month return -63.36
1 year return -72.49
3 year return -77.51
5 year return -85.2
10 year return -

Aldeyra Therapeutics Inc Institutional Holdings

Knoll Capital Management LP 9.10

Perceptive Advisors LLC 8.68

BlackRock Inc 6.32

Vanguard Group Inc 6.15

Kingdon Capital Management LLC 3.07

Vanguard Total Stock Mkt Idx Inv 2.97

D. E. Shaw & Co LP 2.66

683 Capital Management LLC 2.54

Ardsley Advisory Partners 2.41

iShares Russell 2000 ETF 2.25

Kennedy Capital Management Inc 2.09

AQR Capital Management LLC 2.04

Geode Capital Management, LLC 1.95

State Street Corp 1.83

Morgan Stanley - Brokerage Accounts 1.80

Jacobs Levy Equity Management, Inc. 1.61

Acadian Asset Management LLC 1.39

Kennedy Small Cap Select 1.15

Dimensional Fund Advisors, Inc. 1.02

Fidelity Small Cap Index 0.89

Vanguard Institutional Extnd Mkt Idx Tr 0.84

Northern Trust Corp 0.68

AZ Fd 1 - AZ Eq - Amer Opps A-EUR Acc 0.65

Bank of America Corp 0.65

iShares Russell 2000 Growth ETF 0.61

Wells Fargo & Co 0.60

Renaissance Technologies Corp 0.58

Kennedy Micro Cap 0.56

Vanguard Explorer Inv 0.55

State St Russell Sm/Mid Cp® Indx SL Cl I 0.52

DWS ESG Biotech LC 0.44

Vanguard Russell 2000 ETF 0.43

Fidelity Extended Market Index 0.43

RBC Private U.S. Small-Cap Eqty Pool F 0.31

State St Russell Sm Cap® Indx SL Cl I 0.31

Vanguard US Momentum Factor ETF 0.28

DFA US Small Cap I 0.27

Vanguard Health Care ETF 0.26

iShares Micro-Cap ETF 0.24

DFA US Micro Cap I 0.23

Aldeyra Therapeutics Inc Market Status

Strong Buy: 5

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

Aldeyra Therapeutics Inc Fundamentals

Market Cap 108.93 M

PB Ratio 2.4617

PE Ratio 0.0

Enterprise Value 54.42 M

Total Assets 72059317.00 M

Volume 10645121

Aldeyra Therapeutics Inc Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-45691710 -45.7M, FY22:-61369285 -61.4M, FY21:-59254195 -59.3M, FY20:-37553729 -37.6M, FY19:-60826831 -60.8M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-63683 -0.1M, Q2/2025:-62282 -0.1M, Q1/2025:-60912 -0.1M, Q3/2024:null 0.0M, Q2/2024:-61631 -0.1M

Quarterly Net worth Q3/2025:-7688341 -7.7M, Q2/2025:-9767312 -9.8M, Q1/2025:-9929501 -9.9M, Q3/2024:-15112983 -15.1M, Q2/2024:-16847572 -16.8M

About Aldeyra Therapeutics Inc & investment objective

Company Information Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Organisation Biotechnology

Employees 8

Industry Biotechnology

CEO Dr. Todd C. Brady M.D., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Aldeyra Therapeutics Inc FAQs

What is the share price of Aldeyra Therapeutics Inc today?

The current share price of Aldeyra Therapeutics Inc is $1.85.

Can I buy Aldeyra Therapeutics Inc shares in India?

Yes, Indian investors can buy Aldeyra Therapeutics Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Aldeyra Therapeutics Inc shares in India?

You can easily invest in Aldeyra Therapeutics Inc shares from India by:

Can I buy fractional shares of Aldeyra Therapeutics Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Aldeyra Therapeutics Inc?

Aldeyra Therapeutics Inc has a market cap of $108.93 M.

In which sector does Aldeyra Therapeutics Inc belong?

Aldeyra Therapeutics Inc operates in the Biotechnology sector.

What documents are required to invest in Aldeyra Therapeutics Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Aldeyra Therapeutics Inc?

The PE ratio of Aldeyra Therapeutics Inc is N/A and the PB ratio is 2.46.